Zenas BioPharma, Inc. (ZBIO)

NASDAQ: ZBIO · USD

$28.7

+1.37 (+5.0%)· Recorded snapshot

Market cap	1.9B
Revenue (ttm)	1M
Net income (ttm)	-484.4M
EPS (ttm)	-$9.05
Shares out	65.2M
Volume	274,066
Beta	-0.88

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1M
Net income (ttm): -484.4M
EPS (ttm): -$9.05
Market cap: 1.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-199

P25 n/aP50 n/aP75 n/a

ROIC-43.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ZBIO indicators

Market & fundamental data

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001953926
Company name	Zenas BioPharma, Inc.
Country	United States
Country code	US
CUSIP number	98937L105
Earnings date	2026-11-11
Earnings time	bmo
Employees	167
Employees change	37
Employees growth	28.46%
Enterprise value	$1.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2024-09-13
Is primary listing	Yes
Is SPAC	No
ISIN number	US98937L1052
Last 10-K release date	2026-03-16
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.9B
Market cap category	Small-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$28.67
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ZBIO
U.S. state	Massachusetts
Website	https://zenasbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-31.57%
EV/Sales	1,498.58x
FCF / EV yield	-15.08%
FCF yield	-12.26%
Forward EV/Sales	29.06x
Forward P/S	35.75x
P/B ratio	7x
P/S ratio	1,843.85x
Price / tangible book value	7.46x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-27,390.1%
Pretax margin	-48,416.4%
Profit per employee	$-2.9M
Revenue per employee	$5,988
ROA	-34.42%
ROCE	-43.07%
ROE	-199.04%
ROIC	-43.58%
SBC / revenue	3,273%
Tax / revenue	22%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Net income growth years	0
Revenue growth	-93.33%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2,000
Depreciation and amortization	$31,000
EBIT	$-273.9M
EBITDA	$-273.9M
EPS	$-9.05
FCF per share	$-3.47
Financing cash flow	$689M
Free cash flow	$-226M
Free cash flow minus SBC	$-258.7M
Gross profit	$-212.5M
Income taxes	$220,000
Investing cash flow	$-309.4M
Net borrowing	$296.6M
Net cash flow	$152.6M
Net income	$-484.4M
Operating cash flow minus SBC	$-258.7M
Operating income	$-273.9M
Revenue	$1M
Stock-based compensation	$32.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.6
Book value per share	$3.90
Debt / equity	1.21
Interest coverage	-11.29
Long-term assets	$47.9M
Long-term liabilities	$388.8M
Net cash (debt)	$345.3M
Net cash / market cap	18.73%
Net cash growth	26.81%
Net debt / equity	-1.4
Piotroski F-Score	2
Property, plant and equipment	$844,000
Shareholders' equity	$247.1M
Tangible book value	$247.1M
Tangible book value per share	$3.90
Total assets	$701.7M
Total cash	$643.1M
Total debt	$297.9M
Total liabilities	$454.6M
WACC	0.38%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$653.8M
Current liabilities	$65.8M
Current ratio	9.93
Net working capital	$-54.3M
Quick ratio	9.78
Working capital	$588M
Working capital turnover	0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-60.52%
Dividend yield	0%
Shareholder yield	-60.52%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$25.48
1D price change	5.02%
1M price change	6.16%
1M total return	6.16%
1W price change	1.53%
1W total return	1.53%
1Y price change	-10.03%
1Y return CAGR	-10.04%
1Y total return	-10.03%
20-day SMA	$27.03
200-day SMA	$24.89
3M price change	-12.83%
3M total return	-12.83%
50-day SMA	$29.59
50-day SMA vs 200-day SMA	50over200
52-week high	$44.60
52-week high date	2025-12-24
52-week low	$13.50
52-week low date	2026-01-05
6M price change	53.9%
6M total return	53.9%
All-time high	$44.60
All-time high date	2025-12-24
All-time low	$5.83
All-time low date	2025-01-28
Average true range (ATR)	$1.87
Average volume	570.6K
Beta (1Y)	0.26
Beta (2Y)	0.38
Beta (5Y)	-0.88
Change from 52-week high	-35.72%
Change from 52-week low	112.37%
Change from all-time high	-35.85%
Change from all-time low	390.74%
Change from open	3.8%
Day's gap	1.17%
Dollar volume	$7.9M
High price	$28.84
Low price	$27.62
Monthly RSI	57.17
Open price	$27.62
Position in 52-week range	86.07%
Premarket change	0.34%
Premarket close	$27.30
Premarket price	$27.39
Previous close	$27.30
Price vs 150-day SMA	12.29%
Price vs 20-day SMA	5.85%
Price vs 200-day SMA	14.95%
Price vs 50-day SMA	-3.31%
Relative volume	0.48
Return from IPO open	54.17%
Return from IPO price	66.41%
RSI	53.66
Sharpe ratio	0.4
Sortino ratio	0.58
Volume	274.1K
Weekly RSI	52.9
YTD price change	-21.21%
YTD total return	-21.21%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	45M
Float percentage	69.08%
Shares change (QoQ)	13.46%
Shares change (YoY)	60.52%
Shares held by insiders	1.52%
Shares held by institutions	94.54%
Shares outstanding	65.2M
Short % of float	26.52%
Short % of shares	18.32%
Short ratio	18.1 days

Deeper analysis on ZBIO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ZBIO report

Is a complete ZBIO research report available?

No complete published report is available for Zenas BioPharma, Inc. (ZBIO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Zenas BioPharma, Inc. (ZBIO)

Price

Financial snapshot

Fair-value bridge

Latest news · ZBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ZBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ZBIO

Frequently asked questions